T-Cell Engineering and Expansion — GMP Issues

[1]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[2]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[3]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[4]  D. Williams,et al.  Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection , 2011, Gene Therapy.

[5]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  T. Schumacher,et al.  Microbead-assisted retroviral transduction for clinical application. , 2010, Human gene therapy.

[7]  M. Sadelain,et al.  Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β‐thalassemia , 2010, Annals of the New York Academy of Sciences.

[8]  H. Heslop,et al.  Adoptive T cell therapy of cancer. , 2010, Current opinion in immunology.

[9]  S. Sleijfer,et al.  T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies , 2010, Expert opinion on biological therapy.

[10]  A. Schambach,et al.  A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration , 2010, Gene Therapy.

[11]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[12]  Z. Izsvák,et al.  Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. , 2009, Methods.

[13]  Y. Durocher,et al.  Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures , 2009, The journal of gene medicine.

[14]  Christopher D Kroenke,et al.  In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. , 2009, Methods.

[15]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[16]  A. Kamen,et al.  Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. , 2009, Human gene therapy.

[17]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[18]  E. Segal,et al.  Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[19]  Christian Stemberger,et al.  Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets. , 2009, Seminars in immunology.

[20]  M. Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current opinion in immunology.

[21]  C. Lamers,et al.  Gibbon Ape Leukemia Virus Poorly Replicates in Primary Human T Lymphocytes: Implications for Safety Testing of Primary Human T Lymphocytes Transduced With GALV-pseudotyped Vectors , 2009, Journal of immunotherapy.

[22]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[23]  T. Schumacher,et al.  TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008 , 2009, Cancer Immunology, Immunotherapy.

[24]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[25]  T. Wu,et al.  Expression of IL‐15RA or an IL‐15/IL‐15RA fusion on CD8+ T cells modifies adoptively transferred T‐cell function in cis , 2009, European journal of immunology.

[26]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[28]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[29]  W. Leonard,et al.  Interleukin 21: a cytokine/cytokine receptor system that has come of age , 2008, Journal of leukocyte biology.

[30]  J. Sampson,et al.  Selective modification of antigen-specific T cells by RNA electroporation. , 2008, Human gene therapy.

[31]  H. Volk,et al.  Impact of cell culture media on the expansion efficiency and T-cell receptor Vbeta (TRBV) repertoire of in vitro expanded T cells using feeder cells. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[32]  E. Shpall,et al.  Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. , 2008, Cancer research.

[33]  S. Sleijfer,et al.  Retroviral vectors for clinical immunogene therapy are stable for up to 9 years , 2008, Cancer Gene Therapy.

[34]  B. Levine.  T lymphocyte engineering ex vivo for cancer and infectious disease , 2008 .

[35]  B. Engels,et al.  Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette , 2008, Journal of Molecular Medicine.

[36]  Y. Durocher,et al.  Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  J. Wagner,et al.  Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  M. Sadelain,et al.  Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. , 2007, Human gene therapy.

[39]  S. Forman,et al.  Manufacturing of Large Numbers of Patient-specific T Cells for Adoptive Immunotherapy: An Approach to Improving Product Safety, Composition, and Production Capacity , 2007, Journal of immunotherapy.

[40]  Daniel G. Miller,et al.  Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. , 2007, Human gene therapy.

[41]  C. June,et al.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[43]  S. Steinberg,et al.  Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[45]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[46]  Jiwang Zhang,et al.  Sterile and disposable fluidic subsystem suitable for clinical high speed fluorescence‐activated cell sorting , 2006, Cytometry. Part B, Clinical cytometry.

[47]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Lamers,et al.  Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer , 2006, Cancer Gene Therapy.

[49]  M. Papa,et al.  Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center. , 2006, The Israel Medical Association journal : IMAJ.

[50]  J. Tolar,et al.  Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. , 2005, Blood.

[51]  C. Bordignon,et al.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.

[52]  J. Ellis.  Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[53]  K. Cornetta,et al.  Retroviral vector production in the National Gene Vector Laboratory at Indiana University , 2005, Gene Therapy.

[54]  K. Cornetta,et al.  Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. , 2005, Human gene therapy.

[55]  Brian Davis,et al.  Generation of a packaging cell line for prolonged large‐scale production of high‐titer HIV‐1‐based lentiviral vector , 2005, The journal of gene medicine.

[56]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  B. Levine,et al.  Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. , 2005, Human gene therapy.

[58]  S. Riddell,et al.  Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  A. Hagenbeek,et al.  Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious , 2003, Gene Therapy.

[60]  T. Blankenstein,et al.  Retroviral vectors for high-level transgene expression in T lymphocytes. , 2003, Human gene therapy.

[61]  Steven A. Rosenberg,et al.  Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients , 2003, Journal of immunotherapy.

[62]  J. Brosnan.  Interorgan amino acid transport and its regulation. , 2003, The Journal of nutrition.

[63]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  C. Lamers,et al.  Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer , 2002, Cancer Gene Therapy.

[65]  A. Khwaja,et al.  Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS® (v2·1) and Isolex® 300i (v2·5) clinical scale devices , 2002, British journal of haematology.

[66]  J. Wagner,et al.  Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. , 2002, Human gene therapy.

[67]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[68]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[69]  P. Moore,et al.  High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. , 2001, Human gene therapy.

[70]  A. Schambach,et al.  Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  M. Remberger,et al.  Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. , 2000, Experimental hematology.

[72]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[73]  T. Blankenstein,et al.  Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. , 2000, Human gene therapy.

[74]  G. Fleuren,et al.  Bispecific antibodies in cancer therapy, from the laboratory to the clinic. , 1999, Journal of immunotherapy.

[75]  I. Chen,et al.  Lentiviral Vectors--the Promise of Gene Therapy Within Reach? , 1999, Science.

[76]  M. Davis,et al.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. , 1999, Journal of immunology.

[77]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[78]  C. Bordignon,et al.  Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. , 1998, Human gene therapy.

[79]  I. Mcniece,et al.  CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices. , 1998, Journal of hematotherapy.

[80]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[81]  David A. Williams,et al.  High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments , 1998, Journal of Virology.

[82]  Craig W. Reynolds,et al.  A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. , 1998, Journal of hematotherapy.

[83]  David A. Williams,et al.  Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. , 1997, Human gene therapy.

[84]  Z. Eshhar.  Tumor-specific T-bodies: towards clinical application , 1997, Cancer Immunology, Immunotherapy.

[85]  C. Lamers,et al.  Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re‐targeted by a bi‐specific monoclonal antibody , 1997, International journal of cancer.

[86]  S. Riddell,et al.  T cell therapy of human CMV and EBV infection in immunocompromised hosts , 1997, Reviews in medical virology.

[87]  D. Martineau,et al.  Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus. , 1997, Human gene therapy.

[88]  S. Rosenberg,et al.  Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. , 1996, Human gene therapy.

[89]  M. Weijtens,et al.  Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. , 1996, Journal of immunology.

[90]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[91]  G. Nabel,et al.  Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[92]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[93]  D. Russell,et al.  Foamy virus vectors , 1996, Journal of virology.

[94]  S. Rosenberg,et al.  T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.

[95]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[96]  A. Mazzoni,et al.  Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. , 1995, Journal of hematotherapy.

[97]  A. Miller,et al.  Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. , 1995, Blood.

[98]  R. Motzer,et al.  Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma , 1995, Cancer.

[99]  R. Blaese,et al.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[101]  C. Lamers,et al.  Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes , 1995, International journal of cancer.

[102]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[103]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[104]  L. Lum,et al.  Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity. , 1994, Clinical immunology and immunopathology.

[105]  P. Noguchi,et al.  The safety of retroviral vectors. , 1993, Human gene therapy.

[106]  E. Braakman,et al.  Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. , 1993, Journal of immunology.

[107]  F. Marshall,et al.  High efficiency gene transfer into primary human tumor explants without cell selection. , 1993, Cancer research.

[108]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[109]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[111]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[112]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[113]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[114]  K. Cornetta,et al.  Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. , 1989, Journal of virological methods.

[115]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[116]  S. Rosenberg,et al.  Studies of serum-free culture medium in the generation of lymphokine activated killer cells. , 1987, Journal of immunological methods.

[117]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[118]  S. Rosenberg,et al.  Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. , 1987, Journal of immunological methods.

[119]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[120]  S. Rosenberg,et al.  Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. , 1986, Journal of immunological methods.

[121]  S. Chattopadhyay,et al.  A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses , 1984, Journal of virology.

[122]  H. Heslop,et al.  Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. , 2012, Cytotherapy.

[123]  D. Powell,et al.  Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. , 2009, Cytotherapy.

[124]  J. Schachter,et al.  Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. , 2009, Cytotherapy.

[125]  K. Pluta,et al.  Use of HIV as a gene transfer vector. , 2009, Acta biochimica Polonica.

[126]  W. Janssen.  Data management in the cell therapy production facility: the batch process record (BPR). , 2008, Cytotherapy.

[127]  S. Sleijfer,et al.  Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. , 2008, Cytotherapy.

[128]  P. Pedrazzoli,et al.  GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. , 2007, Cytotherapy.

[129]  L. Cooper,et al.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. , 2007, Cytotherapy.

[130]  S. Forman,et al.  Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. , 2006, Cytotherapy.

[131]  S. Sleijfer,et al.  Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. , 2006, Cytotherapy.

[132]  A. Gee,et al.  Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. , 2003, Cytotherapy.

[133]  S. Burger.  Current regulatory issues in cell and tissue therapy. , 2003, Cytotherapy.

[134]  R. Debets,et al.  Genetic engineering of T cell specificity for immunotherapy of cancer. , 2003, Human immunology.

[135]  K. Cornetta,et al.  Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors. , 2001, Human gene therapy.

[136]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[137]  W F Anderson,et al.  Improved methods of retroviral vector transduction and production for gene therapy. , 1994, Human gene therapy.

[138]  T. Dull,et al.  kat: A high-efficiency retroviral transduction system for primary human T lymphocytes , 1994 .

[139]  A. Lanzavecchia,et al.  Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[140]  Xian-Yang Zhang,et al.  LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping , 2022 .